Publications by authors named "Lorea Aguinaga"
The prognostic impact of monocytic differentiation in patients with acute myeloid leukemia (AML) receiving venetoclax (Ven) and azacitidine (Aza) remains unclear. In a prospective cohort of 86 newly diagnosed patients with AML treated with Ven-Aza, we used multiparametric flow cytometry (MFC) to define monoblasts as AML blasts coexpressing ≥2 monocytic markers (CD4, CD36, and CD64) per European LeukemiaNet (ELN) guidelines. Patients with higher monoblasts/CD45+ proportions had lower complete response rates (odds ratio, 0.
View Article and Find Full Text PDFProspective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia.
Cytometry B Clin Cytom
January 2025
BH3 profiling can assess global mitochondrial priming and dependence of leukemic cells on specific BH3 anti-apoptotic proteins such as BCL-2. In acute myeloid leukemia (AML), proof-of-concept prognostic studies have been performed on archived samples variably accounting for molecular genetics. We undertook a single-center feasibility study of a simplified flow-based assay to determine the absolute mitochondrial priming and BCL-2 dependence in consecutive AML patients.
View Article and Find Full Text PDFArticle Synopsis
- Hodgkin lymphoma during pregnancy is rare and needs special care from doctors because of the mother and baby's health.
- Doctors must consider the stage of the disease, which trimester the mother is in, and what the mother wants.
- Research shows that using fewer drugs than usual can still be very effective and safe for both the mom and baby, leading to great results without serious issues.
Article Synopsis
- Acute myeloid leukaemia (AML) is a complex cancer marked by various genetic abnormalities and a heightened oxidative stress environment, making it a target for redox-based therapies.
- Research has shown that the combination of auranofin (AUF), a drug initially used for rheumatoid arthritis, and vitamin C (VC) effectively kills different leukemia cell lines by increasing reactive oxygen species and inhibiting protein synthesis.
- Testing on 22 primary AML samples revealed that this drug combination can effectively eliminate leukaemic cells while being less harmful to normal cells, suggesting a promising anti-AML treatment strategy.
Article Synopsis
- MDM2 and MDM4 are proteins that regulate the p53 tumor suppressor, often overexpressed in cancers, leading to clinical trials targeting their interaction with p53.
- A study of bone marrow samples from 111 patients with various types of leukemia found low protein levels of MDM2 and MDM4 in those with high marrow blasts (>5%), while mRNA levels remained similar across samples.
- The low protein expression of MDM2 and MDM4 was linked to worse survival outcomes, highlighting a disconnect between mRNA and protein levels and suggesting a reevaluation of using MDM2 and MDM4 inhibitors in advanced myeloid cancers.
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.
Future Sci OA
November 2019
Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.
Patients & Methods: The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry.
Results: We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment.
Aim: Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity.
Objective: Investigate the effects on the human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL).
Method: To evaluate these effects, we analyzed the distribution of CD4 and CD8 T cells, B cells and NK cells in the peripheral blood of eight CLL patients who were treated with obinutuzumab in monotherapy.